Tonix Pharmaceuticals (TNXP) Reaches New 1-Year Low at $3.34

Share on StockTwits

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares hit a new 52-week low during trading on Thursday . The company traded as low as $3.34 and last traded at $3.42, with a volume of 6948 shares trading hands. The stock had previously closed at $4.22.

The firm has a market cap of $4.47 million, a P/E ratio of -0.10 and a beta of 1.30.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Friday, November 9th. The company reported ($5.70) EPS for the quarter, beating analysts’ consensus estimates of ($6.10) by $0.40. Research analysts expect that Tonix Pharmaceuticals Holding Corp will post -23.5 EPS for the current fiscal year.

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Renaissance Technologies LLC increased its position in shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) by 66.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 179,300 shares of the company’s stock after acquiring an additional 71,300 shares during the period. Renaissance Technologies LLC owned approximately 2.15% of Tonix Pharmaceuticals worth $798,000 at the end of the most recent quarter. 5.56% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/4001416/tonix-pharmaceuticals-tnxp-reaches-new-1-year-low-at-3-34.html.

Tonix Pharmaceuticals Company Profile (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.

Read More: What strategies should day traders use to execute a trade?

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

PennantPark Investment   Shares Down 0.3%
PennantPark Investment Shares Down 0.3%
Digital Turbine  Stock Price Down 3.2%
Digital Turbine Stock Price Down 3.2%
Head-To-Head Analysis: Wesco Aircraft  vs. Resideo Technologies
Head-To-Head Analysis: Wesco Aircraft vs. Resideo Technologies
Head to Head Survey: Microwave Filter  & Vicor
Head to Head Survey: Microwave Filter & Vicor
Royal Kingdom Coin Reaches Market Cap of $4,417.00
Royal Kingdom Coin Reaches Market Cap of $4,417.00
Sorrento Therapeutics   Shares Down 5.3%
Sorrento Therapeutics Shares Down 5.3%


Leave a Reply

© 2006-2018 Ticker Report